Analyzing OncoSec Medical (ONCS) and Charles River Laboratories International (CRL)
OncoSec Medical (NASDAQ: ONCS) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Valuation and Earnings
This table compares OncoSec Medical and Charles River Laboratories International’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|OncoSec Medical||N/A||N/A||-$21.73 million||($1.17)||-1.07|
|Charles River Laboratories International||$1.81 billion||3.03||$435.89 million||$3.81||30.23|
Charles River Laboratories International has higher revenue and earnings than OncoSec Medical. OncoSec Medical is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
This table compares OncoSec Medical and Charles River Laboratories International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories International||10.13%||27.02%||8.84%|
Insider and Institutional Ownership
9.0% of OncoSec Medical shares are owned by institutional investors. Comparatively, 95.1% of Charles River Laboratories International shares are owned by institutional investors. 11.5% of OncoSec Medical shares are owned by insiders. Comparatively, 2.2% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for OncoSec Medical and Charles River Laboratories International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories International||0||5||4||0||2.44|
OncoSec Medical currently has a consensus target price of $5.33, indicating a potential upside of 326.33%. Charles River Laboratories International has a consensus target price of $103.17, indicating a potential downside of 10.42%. Given OncoSec Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe OncoSec Medical is more favorable than Charles River Laboratories International.
Risk & Volatility
OncoSec Medical has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Charles River Laboratories International beats OncoSec Medical on 7 of the 12 factors compared between the two stocks.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.